Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 10/20 | 0.41 |
| ▸ | CDC25B | P30305 | 8/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 6/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.37 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.37 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.37 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TACR2 | P21452 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2530519 | 0.87 | TACR2 (0.43) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL11514915 | 0.85 | SSTR1 (0.42) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL11511613 | 0.85 | SSTR1 (0.42) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL9800967 | 0.84 | SSTR1 (0.42) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL2484235 | 0.84 | TYMP (0.39) | — | |
| SCHEMBL7901248 | 0.83 | SSTR1 (0.43) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL16581497 | 0.83 | SSTR1 (0.43) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL9800968 | 0.81 | NT5E (0.48) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL11512349 | 0.79 | FGF1 (0.39) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL11511596 | 0.79 | SSTR5 (0.38) | NT5ESSTR1SSTR2SSTR4SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4212541-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES AND THEIR INTERMEDIATES | Genzyme Corporation (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20220242899-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION | 2022-08-04 | — | — | US | disclosed |
| US-11279725-B2 | Oligosaccharide-protein conjugates | GENZYME CORPORATION (US) | 2022-03-22 | — | — | US | disclosed |
| US-20200216485-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION | 2020-07-09 | — | — | US | disclosed |
| EP-3608330-A2 | SYNTHETIC INTERMEDIATES FOR PREPARING OLIGOSACCHARIDE-PROTEIN CONJUGATES | Genzyme Corporation (US) | 2020-02-12 | — | — | EP | disclosed |
| US-10464962-B2 | Oligosaccharide-protein conjugates | GENZYME CORPORATION (US) | 2019-11-05 | — | — | US | disclosed |
| EP-2889043-B1 | Synthetic intermediates for preparing oligosaccharide-protein conjugates | GENZYME CORP (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20180002365-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION | 2018-01-04 | — | — | US | disclosed |
| US-9493498-B2 | Oligosaccharide-protein conjugates | GENZYME CORPORATION (US) | 2016-11-15 | — | — | US | disclosed |
| EP-2889043-A2 | Oligosaccharide-protein conjugates | Genzyme Corporation (US) | 2015-07-01 | — | — | EP | disclosed |
| US-20150175643-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION | 2015-06-25 | — | — | US | disclosed |
| EP-2465542-B1 | Oligosaccharide-protein conjugates | GENZYME CORP (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8835614-B2 | Oligosaccharide-protein conjugates | GENZYME CORPORATION (US) | 2014-09-16 | — | — | US | disclosed |
| EP-2465542-A1 | Oligosaccharide-protein conjugates | Genzyme Corporation (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20110300120-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION | 2011-12-08 | — | — | US | disclosed |
| EP-2376123-A2 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | Genzyme Corporation (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010075010-A2 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242899-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | MAN2B1, GAA, GBA1 | NT5E 2722/4885PTPN1 3109/4885CDC25B 4212/4885 |
| US-20200216485-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | MAN2B1, GAA, GBA1 | NT5E 2722/4885PTPN1 3109/4885CDC25B 4212/4885 |
| US-20110300120-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | MAN2B1, GAA, GBA1 | NT5E 2722/4885PTPN1 3109/4885CDC25B 4212/4885 |
| US-20150175643-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | MAN2B1, GAA, GBA1 | NT5E 2722/4885PTPN1 3109/4885CDC25B 4212/4885 |
| US-10464962-B2 | Oligosaccharide-protein conjugates | MAN2B1, GAA, GBA1 | NT5E 2722/4885PTPN1 3109/4885CDC25B 4212/4885 |
| US-11279725-B2 | Oligosaccharide-protein conjugates | MAN2B1, GAA, GBA1 | NT5E 2722/4885PTPN1 3109/4885CDC25B 4212/4885 |
| US-20180002365-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | MAN2B1, GAA, GBA1 | NT5E 2722/4885PTPN1 3109/4885CDC25B 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.